Hemady (Dexamethasone) Patent Expiration, LOE Window & CMS Spending
Hemady (Dexamethasone) by Dexcel Technologies: FDA Orange Book LOE 2037-12-18, 15 AB generics, $130K 2024 CMS Part D & Medicaid spend, and $2,740 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Dexcel Technologies |
| FDA Application & Pathway | N211379 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2037-12-18 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 15 |
| 2024 CMS Total Public Spend | $130K |
| 2024 Medicare Part D Spend | $120K |
| 2024 Medicaid Spend | $10K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,740 intro WAC) |